Learn To Invest
Stocks Special Reports LICs Credit Funds ETFs Tools SMSFs
Video Archive Article Archive
News Stocks Special Reports Funds ETFs Features SMSFs Learn

Company News Summary

Avita Medical Enters into Collaboration to Explore Potential Spray-On Treatment of Genetically Modified Cells for Epidermolysis Bullosa

25 Nov 2019  |  09:21:00  |  Associate analysts  |  Increase  |  Decrease  |  

Original announcement: AVITA Medical, CU Denver Announce Preclinical Collaboration

Avita Medical announced a preclinical research collaboration to establish proof-of-concept and explore further development of a spray-on treatment of genetically modified cells for patients with epidermolysis bullosa (EB), with potential applicability to other genetic skin disorders. The partnership will pair its patented and proprietary Spray-On Skin Cells technology and expertise with the Gates Center's innovative, patent pending combined reprogramming and gene editing technology to allow cells to function properly. Under the terms of the Sponsored Research Agreement (SRA), it will retain the option to exclusively license technologies emerging from the partnership for further development and commercialization.

Please click here for full details

See more ASX300 News Announcements